- Home
- BDRX vs QNRX Comparison
BDRX vs QNRX Comparison
Compare BDRX & QNRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BDRX
- QNRX
- Stock Information
- Founded
- BDRX 2000
- QNRX 2018
- Country
- BDRX United Kingdom
- QNRX United States
- Employees
- BDRX N/A
- QNRX N/A
- Industry
- BDRX Biotechnology: Pharmaceutical Preparations
- QNRX Medical/Dental Instruments
- Sector
- BDRX Health Care
- QNRX Health Care
- Exchange
- BDRX Nasdaq
- QNRX Nasdaq
- Market Cap
- BDRX 3.8M
- QNRX 4.4M
- IPO Year
- BDRX N/A
- QNRX N/A
- Fundamental
- Price
- BDRX $6.07
- QNRX $7.70
- Analyst Decision
- BDRX
- QNRX
- Analyst Count
- BDRX 0
- QNRX 0
- Target Price
- BDRX N/A
- QNRX N/A
- AVG Volume (30 Days)
- BDRX 49.7K
- QNRX 2.5K
- Earning Date
- BDRX 09-29-2025
- QNRX 11-06-2025
- Dividend Yield
- BDRX N/A
- QNRX N/A
- EPS Growth
- BDRX N/A
- QNRX N/A
- EPS
- BDRX N/A
- QNRX N/A
- Revenue
- BDRX N/A
- QNRX N/A
- Revenue This Year
- BDRX N/A
- QNRX N/A
- Revenue Next Year
- BDRX N/A
- QNRX N/A
- P/E Ratio
- BDRX N/A
- QNRX N/A
- Revenue Growth
- BDRX N/A
- QNRX N/A
- 52 Week Low
- BDRX $5.00
- QNRX $5.01
- 52 Week High
- BDRX $108.90
- QNRX $54.95
- Technical
- Relative Strength Index (RSI)
- BDRX 45.24
- QNRX 54.87
- Support Level
- BDRX $5.00
- QNRX $7.37
- Resistance Level
- BDRX $6.32
- QNRX $7.79
- Average True Range (ATR)
- BDRX 0.52
- QNRX 0.12
- MACD
- BDRX 0.12
- QNRX 0.05
- Stochastic Oscillator
- BDRX 54.27
- QNRX 87.32
About BDRX Biodexa Pharmaceuticals plc
Biodexa Pharmaceuticals PLC is a clinical-stage biopharmaceutical company focused on developing a pipeline of products to treat diseases that have unmet medical needs. These include familial adenomatous polyposis (FAP), non-muscle invasive bladder cancer (NMIBC), type 1 diabetes (T1D), and rare or orphan brain cancers.
About QNRX Quoin Pharmaceuticals Ltd.
Quoin Pharmaceuticals Ltd is a clinical stage specialty pharmaceutical company focused on developing and commercializing therapeutic products that treat rare and orphan diseases. Its pipeline comprises three products that collectively have the potential to target a broad number of rare and orphan indications, including Netherton Syndrome, Peeling Skin Syndrome, Palmoplantar Keratoderma, Epidermolysis Bullosa, and others.